Ind-Swift Laboratories Ltd - IND-SWIFT LABS. Share Price

Sector: Pharmaceuticals | ISIN: INE915B01019
₹ 110.00 (-0.95%) icon21 Feb, 2024, 10:24:11 AM
Open
₹ 111.90
Prev. Close
₹ 111.05
Turnover(lac)
₹ 0.00
Day's High
₹ 112.00
Day's Low
₹ 109.35
52 Wk High
₹ 123.40
52 Wk Low
₹ 53.95
Book Value
₹ 94.78
Face Value
₹ 10.00
Mkt. Cap (Cr.)
₹ 649.96
P/E
26.33
EPS
4.24
Div. Yield
0.00

Ind-Swift Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/21/2024 10:24:11 AM

    ₹ 110 -1.05 -0.95
  • Open
  • ₹ 111.9
  • Prev. Close
  • ₹ 111.05
  • Turnover(Lac.)
  • ₹ 60
  • Day's High
  • ₹ 112
  • Day's Low
  • ₹ 109.35
  • 52 Week's High
  • ₹ 123.4
  • 52 Week's Low
  • ₹ 53.95
  • Book Value
  • ₹ 94.78
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 649.96
  • P/E
  • 26.33
  • EPS
  • 4.24
  • Divi. Yield
  • 0

Ind-Swift Laboratories Ltd Corporate Actions

29 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jan , 2024

12:00 AM

30 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Oct , 2023

12:00 AM

06 Sep , 2023

12:00 AM

31 Aug , 2023

12:00 AM

AGM

Announcement date: 31 Aug , 2023

View Details

25 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

16 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

16 Aug , 2023

12:00 AM

BookCloser

View Details

31 Aug , 2023

12:00 AM

BookCloser

View Details

12 Sep , 2023

12:00 AM

BookCloser

View Details

Ind-Swift Laboratories Ltd News and Update

Image not found
  • 1 day ago |
  • 12:02 AM

This strategic move aligns with the company's vision for expansion and consolidation in the pharmaceutical sector.

Image not found
  • IIFL News Service |
  • 16 February, 2024 |
  • 11:57 PM
Image not found
  • IIFL News Service |
  • 15 February, 2024 |
  • 11:56 PM
Article Image

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Ind-Swift Laboratories Ltd SHAREHOLDING SNAPSHOT
21 February , 2024 | 10:42 AM

PROMOTER - TOTAL42.00%

Indian: 42.00%

Foreign: 0%

NON-PROMOTER - TOTAL 58.00%

Institutions: 19.04%

Non-Institutions: 38.95%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Ind-Swift Laboratories Ltd FINANCIALS

Ind-Swift Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Ind-Swift Laboratories Ltd

  • N R Munjal
  • Chairman & Managing Director
  • Himanshu Jain
  • Joint Managing Director
  • Pradeep Verma
  • Company Sec. & Compli. Officer
  • Rishav Mehta
  • Executive Director
  • S P Sharma
  • Independent Director
  • Neerja Chathley
  • Independent Director
  • Ashwani K Vig
  • Independent Director
  • Sahil Munjal
  • Executive Director
  • Rajendra Kumar Gupta
  • Independent Director

Summary

Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.Ind-Swift Laboratories Ltd was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they... Read More


Reports by Ind-Swift Laboratories Ltd


Reports by Ind-Swift Laboratories Ltd

Company FAQ

No Record Found